NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)
ID: 350657Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350657

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-050.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)." This initiative aims to support well-designed clinical trials that focus on effective interventions for communication disorders, including those requiring FDA oversight or presenting higher risks to participants. The program emphasizes inclusive participation from various eligible applicants, including educational institutions, governmental agencies, and nonprofit organizations, particularly those representing underrepresented groups. Interested parties can find more information and application guidelines at the provided link, with a submission deadline of October 27, 2026. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-050-Full-Announcement.html
    PAR-24-050.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), offers a funding opportunity titled "NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)." This initiative focuses on supporting well-designed clinical trials aimed at effective interventions for communication disorders such as hearing and speech impairments. The program invites applications that necessitate FDA oversight or have higher participant risks, with specific criteria for funding based on project costs or risk levels. Eligible applicants include various educational, governmental, and nonprofit organizations, with an emphasis on inclusive participation from underrepresented groups. The application process involves strict adherence to submission guidelines and prioritizes projects demonstrating significant scientific merit and community engagement. The anticipated funding outcomes align with NIH's goals to improve clinical practices and inform health policies. Significant involvement from NIH staff in project activities post-award is also a hallmark of this funding mechanism, underscoring the cooperative nature of the agreement.
    Similar Opportunities
    NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity for low-risk clinical trials in communication disorders under Funding Opportunity Number PAR-24-051. This initiative aims to support investigator-initiated projects that develop effective interventions in areas such as hearing, speech, and language, specifically targeting low-risk clinical trials that do not require FDA oversight and adhere to budget limits of under $500,000 in direct costs per year. The funding is particularly significant for enhancing research in communication disorders, ultimately improving public health outcomes through scientifically validated interventions. Interested applicants can submit proposals starting January 5, 2024, with the opportunity closing on January 8, 2028; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Deafness and Other Communication Disorders (NIDCD), is offering Clinical Research Center Grants (P50) aimed at advancing the diagnosis, prevention, treatment, and amelioration of human communication disorders. The grants support interdisciplinary research teams focusing on various communication issues, including those related to hearing, balance, smell, taste, voice, speech, and language, with applications permitted for low-risk clinical trials, although they are not mandatory. Eligible applicants include a wide range of institutions such as public and private higher education institutions, nonprofits, and local and state governments, with budgets capped at $1.5 million per year for a maximum project period of five years. Interested parties should submit their applications by October 9, 2024, and can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Early-Stage Dissemination and Implementation Research in Communication Disorders" under the R21 grant mechanism. This initiative aims to support early-stage research projects that enhance the dissemination and implementation of evidence-based innovations (EBIs) in areas such as hearing, speech, balance, taste, and language, with a focus on addressing barriers to adoption in clinical settings. The funding opportunity will provide approximately $1 million, with individual project budgets capped at $275,000 over a two-year period, and applications are due by October 12, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Dissemination and Implementation Research in Communication Disorders Conference (U13 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Deafness and Other Communication Disorders (NIDCD), is inviting proposals for the organization of an annual conference focused on Dissemination and Implementation (D&I) Research in Communication Disorders. The objective of this cooperative agreement is to enhance the capacity of participants to conduct high-quality D&I research across various domains, including hearing, balance, taste, smell, voice, speech, and language, while promoting diversity and inclusion among attendees. This initiative is critical for advancing the understanding and adoption of evidence-based practices in clinical settings. The total funding available for this opportunity is $100,000, with applications due by October 25, 2024, and funding decisions expected by March 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)" aimed at stimulating research related to communication disorders associated with HIV/AIDS. This initiative encourages innovative, hypothesis-driven research that addresses high-priority areas such as hearing, speech, and language, with a focus on low-risk clinical trials that do not require FDA oversight. Eligible applicants include a wide range of organizations, such as higher education institutions and community-based organizations, with funding available up to $499,999 per year for projects lasting up to five years. Interested parties should submit their applications by January 7, 2026, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the announcement page at https://grants.nih.gov/grants/guide/pa-files/PAR-23-099.html.
    NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated efficacy clinical trials through the NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) program. This initiative aims to support clinical studies that evaluate drugs, biologics, devices, and various interventions targeting neurological disorders, requiring a phased approach where UG3 planning must precede UH3 execution. The trials must be well-designed with robust scientific rationale and diverse participant inclusion, emphasizing collaboration with patient advocacy groups and national networks. Interested applicants can find more information and application guidelines at the provided NIH link, with a submission deadline of January 9, 2025, and no cost-sharing or matching requirements. For inquiries, contact the NIH OER Webmaster at grantsinfo@nih.gov.
    NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Notice of Funding Opportunity (NOFO) for the NIAID Clinical Trial Implementation Cooperative Agreement (U01), aimed at supporting high-risk clinical trials that enhance the understanding of human diseases. This funding opportunity encourages applications for investigator-initiated, milestone-driven clinical trials, with each application permitted to propose only one clinical trial that must demonstrate a hypothesis-driven approach. The initiative emphasizes the importance of mechanistic studies within clinical trials and requires a robust plan for managing trial complexity and participant safety. Interested applicants can find additional details and guidelines at the provided NIH link, with the earliest submission date set for April 12, 2024, and the application deadline on January 13, 2027. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Research Experiences to Enhance Clinician-Scientists' Participation in NIDCDs Research (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Experiences to Enhance Clinician-Scientists' Participation in NIDCD’s Research" under the R25 Clinical Trial Not Allowed grant program. This initiative aims to recruit and prepare clinician researchers, particularly from underrepresented groups, by providing hands-on research experiences and developing scientific skills in areas related to hearing, balance, taste, smell, voice, speech, and language research. The program emphasizes the importance of diversity in participant recruitment and requires an effective evaluation and dissemination plan, with a maximum funding amount of $250,000 per year for projects lasting up to five years. Interested applicants must submit their proposals by October 1, 2024, and can reach out to the NIH OER Webmaster at grantsinfo@nih.gov for further assistance.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that address critical questions related to neurological disorders, focusing on studies involving drugs, biologics, devices, and early interventions. The program emphasizes rigorous research design and encourages diverse and innovative research teams, with grants potentially spanning up to five years, beginning with a planning phase before transitioning to execution. Interested applicants can find more information and application details at the provided link, with a submission deadline of March 10, 2025, and no cost-sharing or matching requirement.